Evoke Pharma Long Term Debt 2012-2025 | EVOK
Evoke Pharma long term debt from 2012 to 2025. Long term debt can be defined as the sum of all long term debt fields.
Evoke Pharma Annual Long Term Debt
(Millions of US $) |
| 2024 |
$0 |
| 2023 |
$0 |
| 2022 |
$5 |
| 2021 |
$5 |
| 2020 |
$5 |
| 2019 |
$0 |
| 2018 |
$0 |
| 2017 |
$0 |
| 2016 |
$0 |
| 2015 |
$4 |
| 2014 |
$4 |
| 2013 |
$2 |
| 2012 |
$1 |
| 2011 |
$0 |
Evoke Pharma Quarterly Long Term Debt
(Millions of US $) |
| 2025-03-31 |
|
| 2024-12-31 |
|
| 2024-09-30 |
|
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
|
| 2023-09-30 |
$5 |
| 2023-06-30 |
$5 |
| 2023-03-31 |
$5 |
| 2022-12-31 |
$5 |
| 2022-09-30 |
$5 |
| 2022-06-30 |
$5 |
| 2022-03-31 |
$5 |
| 2021-12-31 |
$5 |
| 2021-09-30 |
$5 |
| 2021-06-30 |
$5 |
| 2021-03-31 |
$5 |
| 2020-12-31 |
$5 |
| 2020-09-30 |
$2 |
| 2020-06-30 |
$2 |
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
|
| 2016-09-30 |
|
| 2016-06-30 |
|
| 2016-03-31 |
$4 |
| 2015-12-31 |
$4 |
| 2015-09-30 |
$4 |
| 2015-06-30 |
$3 |
| 2015-03-31 |
$4 |
| 2014-12-31 |
$4 |
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
$1 |
| 2013-12-31 |
$2 |
| 2013-09-30 |
$2 |
| 2013-06-30 |
$2 |
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.005B |
$0.010B |
|
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
|
